2013 Mariam Al-Omari JORDAN supervisor: Prof. Dr. Janciauskiene, Pulmonology, OE 6870, project: Studies on the link between Alpha-1-Antitrypsin deficiency, respiratory viral infection and development of [...] Hansen, Pediatric Pneumology, OE 6710, project: Maternofetal transfer of an immunological memory - studies in a murine asthma model Final exam June 2014 Insa Hoffmann (Dr.med.) Germany supervisor: Prof. Dr
prior infection or vaccination, requiring vaccine adaptation. Within the frame of the ongoing CoCo Study, we analyzed the immunogenicity of an adapted vaccine, BNT162b2 Omicron XBB.1.5, which is currently
purinergic signalling pathways in acute and chronic liver diseases, including liver cancer. Recent studies have shown that HCC cells, like cirrhotic liver tissue, express adenosinergic P1 receptors and several
various applications, including teratogenicity assessment as well as organ development and disease studies. Expanding on the first description of the HFO model in Nature Biotechnology (featured on the cover
stress conditions. The second line of the research that is actively conducted in my lab is focused on studying the role of the microRNA pathway in stem cells, where the Drosophila germline and neuronal stem
in their nuclei. In parallel, we are generating additional „knock-in“ und „knock-out” models to study the function of γδ T cells and other innate lymphocytes.
Sabine Pirr is a specialist for pediatrics and adolescent medicine with a focus on neonatology. She studied human medicine in Halle, Leipzig, Cologne and Zurich. Her training and further education as a pe
Prof. Dr. med. Ulrich Baumann is a specialist in pediatrics and adolescent medicine. He studied medicine in Göttingen, Bremen and Chur (Switzerland) and completed his training as a pediatrician in Bremen
Network (international effort to rapidly repurpose existing drugs against COVID-19) International studies (therapy and diagnostics)
Mark-Christian Jaboreck (RG Martin): “Development of a hiPSC-based cystic fibrosis lung disease model to study TMEM16A as an alternative therapeutic target in cystic fibrosis” Mikhail Magdei (RG Hilfiker): “Analysis